Drugs / tyrosinase
tyrosinase
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00698100 | Jun 2002 → Sep 2011 | melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003792 | Apr 1999 → Oct 2006 | cutaneous melanoma | Baylor Health Care System | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00084656 | May 2004 → Oct 2009 | cutaneous melanoma, ocular melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00006385 | Sep 2000 → Oct 2006 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00036816 | Feb 2002 → Feb 2003 | uveal melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tyrosinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036816 ↗ |
| Known as | human tyrosinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698100 ↗ |
| Known as | Tyrosinase/gp100/MART-1 Peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00084656 ↗ |
| Modality | Peptide | “tyrosinase peptide” NCT00003792 ↗ |
| Route | Subcutaneous | “peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen emulsified in Montanide ISA-51 subcutaneously” NCT00084656 ↗ |